JP2023503898A - フルベストラントのプロドラッグ - Google Patents

フルベストラントのプロドラッグ Download PDF

Info

Publication number
JP2023503898A
JP2023503898A JP2022529452A JP2022529452A JP2023503898A JP 2023503898 A JP2023503898 A JP 2023503898A JP 2022529452 A JP2022529452 A JP 2022529452A JP 2022529452 A JP2022529452 A JP 2022529452A JP 2023503898 A JP2023503898 A JP 2023503898A
Authority
JP
Japan
Prior art keywords
optionally substituted
aryl
heteroaryl
group
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503898A5 (https=
Inventor
パーバ・ヨーゲシチャンドラ・プロヒット
パシック・スバースチャンドラ・ブラームクシャトリヤ
ヴィシャルギリ・ガンヴァントギリ・ゴスワミ
Original Assignee
カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー filed Critical カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Publication of JP2023503898A publication Critical patent/JP2023503898A/ja
Publication of JP2023503898A5 publication Critical patent/JP2023503898A5/ja
Priority to JP2025202023A priority Critical patent/JP2026032104A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022529452A 2019-11-24 2020-11-24 フルベストラントのプロドラッグ Pending JP2023503898A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202023A JP2026032104A (ja) 2019-11-24 2025-11-21 フルベストラントのプロドラッグ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921047986 2019-11-24
IN201921047986 2019-11-24
IN202021029084 2020-07-08
IN202021029084 2020-07-08
PCT/IB2020/061065 WO2021100029A2 (en) 2019-11-24 2020-11-24 Prodrugs of fulvestrant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202023A Division JP2026032104A (ja) 2019-11-24 2025-11-21 フルベストラントのプロドラッグ

Publications (2)

Publication Number Publication Date
JP2023503898A true JP2023503898A (ja) 2023-02-01
JP2023503898A5 JP2023503898A5 (https=) 2023-12-18

Family

ID=75980095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529452A Pending JP2023503898A (ja) 2019-11-24 2020-11-24 フルベストラントのプロドラッグ
JP2025202023A Pending JP2026032104A (ja) 2019-11-24 2025-11-21 フルベストラントのプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202023A Pending JP2026032104A (ja) 2019-11-24 2025-11-21 フルベストラントのプロドラッグ

Country Status (7)

Country Link
US (1) US20230137764A1 (https=)
EP (1) EP4061376A4 (https=)
JP (2) JP2023503898A (https=)
CN (1) CN115151260A (https=)
AU (1) AU2020386864A1 (https=)
CA (1) CA3162182A1 (https=)
WO (1) WO2021100029A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4422636A4 (en) * 2021-10-29 2025-09-03 Kashiv Biosciences Llc INECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BREAST CANCER
WO2023103929A1 (zh) * 2021-12-06 2023-06-15 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN114716496B (zh) * 2022-04-29 2024-04-02 香港中文大学（深圳） 氟维司群衍生物及氟维司群衍生物制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158644A2 (en) * 2012-04-16 2013-10-24 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015038649A1 (en) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
JP2016517849A (ja) * 2013-04-18 2016-06-20 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法
JP2016539077A (ja) * 2013-04-18 2016-12-15 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． ７−α−［９−（４，４，５，５，５−ペンタフルオロ−ペンチル−スルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオール及びその誘導体の使用
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
WO2019224790A2 (en) * 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CN103421069A (zh) * 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158644A2 (en) * 2012-04-16 2013-10-24 Synta Pharmaceuticals Corp. Targeted therapeutics
JP2016517849A (ja) * 2013-04-18 2016-06-20 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法
JP2016539077A (ja) * 2013-04-18 2016-12-15 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． ７−α−［９−（４，４，５，５，５−ペンタフルオロ−ペンチル−スルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオール及びその誘導体の使用
WO2015038649A1 (en) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
WO2019224790A2 (en) * 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Also Published As

Publication number Publication date
WO2021100029A2 (en) 2021-05-27
EP4061376A2 (en) 2022-09-28
EP4061376A4 (en) 2024-03-13
US20230137764A1 (en) 2023-05-04
AU2020386864A1 (en) 2022-06-16
CA3162182A1 (en) 2021-05-27
JP2026032104A (ja) 2026-02-25
WO2021100029A3 (en) 2021-07-01
CN115151260A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
JP7653092B2 (ja) フルベストラントのプロドラッグ
JP2026032104A (ja) フルベストラントのプロドラッグ
ES3060188T3 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
ES2628953T3 (es) Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
ES2731758T3 (es) Derivados de alcanodiil y alquenodiil de c17 del ácido oleanólico y métodos de uso de los mismos
CA2923075C (en) Aza-pyridone compounds and uses thereof
JP7688912B2 (ja) キノリンおよびキナゾリン化合物およびその使用方法
JP2021527666A (ja) Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
US20220098211A1 (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
JP7759063B2 (ja) プロドラッグ化合物、その製造方法、及び用途
AU2014348518A1 (en) Azepane derivatives and methods of treating hepatitis B infections
TWI870449B (zh) 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法
ES2626246T3 (es) Derivado de 8-oxodihidropurina
CA3107377A1 (en) Boronic acid derivatives
JP2011529907A (ja) イソホスホルアミドマスタードおよびその類似体の合成および製剤
US9751911B2 (en) Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof
KR102961556B1 (ko) 프로드러그 화합물 및 이의 제조 방법과 용도
CA3031562C (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
TW200918065A (en) Imidazopyridazine derivatives
WO2026078657A1 (en) Prodrugs of riluzole
JP2024542821A (ja) 癌治療のための化合物
BR122023025728A2 (pt) Derivados de 10-(di(fenil)metil)-4-hidróxi-8,9,9a-10-tetra-hidro-7hpirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona e compostos relacionados como inibidores de da replicação de ortomixovírus, seus usos para tratamento de influenza, composição farmacêutica, e combinação

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805